Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Zhaoke Ophthalmology Ltd. ( (HK:6622) ).
Zhaoke Ophthalmology Limited has entered into three distribution agreements with Interpharma to commercialize NVK002, BRIMOCHOL™ PF, and six glaucoma drugs in Thailand. These agreements grant Interpharma exclusive rights to import, distribute, and sell these products, potentially enhancing Zhaoke’s market presence in Southeast Asia and expanding access to innovative ophthalmic treatments.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company focused on the ophthalmology industry, providing innovative treatments and generic drugs for eye conditions. Their primary products include NVK002 for myopia progression control, BRIMOCHOL™ PF for presbyopia, and several drugs targeting glaucoma.
YTD Price Performance: 28.33%
Average Trading Volume: 2,643,883
Technical Sentiment Signal: Buy
Current Market Cap: HK$852M
For detailed information about 6622 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue